Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals

Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals
 
 Company Expands Product Portfolio, Adds Drug Delivery Technology
SAN DIEGO, Aug. 3 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") today  announced  that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc. (OTCQB: MBRKQ).

Through the acquisition, Victory Pharma has expanded its product portfolio with the addition of anti-infective  products  MOXATAG® and KEFLEX® as well as the PULSYS® drug delivery technology platform.  The product additions complement Victory's current products, such as NAPRELAN®, which the company markets to primary care and specialist physicians.

"This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products," said Matt Heck, president and chief executive officer of  Victory  Pharma.  "The addition of  these products balances our portfolio nicely, as NAPRELAN's highest period of utilization is in the spring and summer, while MOXATAG's utilization peaks during the flu season.  And we believe MOXATAG will substantially benefit from our management team's prior, successful experience marketing anti-infective products."

MOXATAG is the only FDA-approved, once-daily formulation of amoxicillin, and is indicated for the treatment of tonsillitis and/or pharyngitis.  MOXATAG utilizes PULSYS technology to deliver drug at set intervals over a 24 hour period, whereas other amoxicillin products require multiple times daily dosing. Reduced dosing frequency can improve therapy compliance, which is potentially important given patient non-compliance is widely-recognized as the primary reason for antibiotic therapy failure 1,2,3, and non-compliant patients have been shown to have a 175 percent greater chance of infection recurrence 4.

About MiddleBrook Pharmaceuticals

MiddleBrook  Pharmaceuticals, Inc. (OTCQB:  MBRKQ) is a company that focused on commercializing anti-infective products to fulfill unmet medical needs. MiddleBrook developed a proprietary delivery technology, PULSYS®, that enables  the pulsatile delivery, or delivery in rapid bursts, of certain drugs. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

About Victory Pharma

Founded in 2003, Victory Pharma Inc. is a privately-held, specialty pharmaceutical company headquartered in San Diego focused on acquiring, developing, and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN® (naproxen sodium) Controlled-Release Tablets, and other pain products to pain management specialists, rheumatologists, orthopedic surgeons, and selected primary care physicians through its physician office-based field sales force.  Further information regarding Victory Pharma is available at www.victorypharma.com.

NAPRELAN® is a trademark of Elan Corporation, plc.


SOURCE Victory Pharma, Inc.

Back to top
RELATED LINKS
http://www.victorypharma.com
http://www.middlebrookpharma.com

 

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.